CureVac GmbH
Paul-Ehrlich-Str. 15
Tübingen
72076
Germany
Tel: 49-7071-92053-0
Fax: 49-7071-92053-11
Website: http://www.curevac.de/
84 articles with CureVac GmbH
-
CureVac: CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate
9/29/2020
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
-
CureVac Announces Pricing of Initial Public Offering
8/14/2020
CureVac B.V. announced the pricing of its initial public offering of 13,333,333 common shares at an initial public offering price of $16.00 per common share, for total gross proceeds of approximately $213.3 million.
-
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering Thursday.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
-
CureVac Announces Proposed Initial Public Offering of Common Shares
8/10/2020
CureVac B.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that it intends to offer and sell in an underwritten public offering of 13,333,333 common shares.
-
The two companies will combine their mRNA research to develop the potential vaccines across a range of infectious disease pathogens.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
-
Germany: EIB and European Commission provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing
7/6/2020
European Investment Bank and CureVac sign €75 million loan agreement for the development and large-scale production of vaccines, including CureVac's vaccine candidate against SARS-CoV-2
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
-
The “printers” are portable, automated messenger RNA (mRNA) production units, which Elon Musk referred to as “RNA microfactories.”
-
BioSpace Global Roundup, June 18
6/18/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
-
Jean Stéphenne Elected as New Chairman of the Supervisory Board of CureVac
4/2/2020
CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, announced that Jean Stéphenne, former deputy Chairman of the Supervisory Board, has been appointed as the new Chairman with immediate effect.
-
There has been something of a furor over reports in the German newspaper Welt am Sonntag that claimed the Trump administration offered a “billion dollars” for exclusive rights to a coronavirus vaccine in development by German company CureVac, “but only for the USA.”
-
CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide
3/15/2020
CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.
-
Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG
3/11/2020
CureVac AG announced that company founder and Chairman of the Supervisory Board, Ingmar Hoerr is replacing Daniel Menichella in his function as Chief Executive Officer.
-
CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force
3/2/2020
Daniel Menichella was invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak’s response.